Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: Adv Mater. 2017 Nov 2;29(47):10.1002/adma.201703969. doi: 10.1002/adma.201703969

Figure 1.

Figure 1

Schematic of CpG-CCNPs for anticancer vaccination. Membrane derived from cancer cells (purple), along with the associated tumor antigens (small colored spheres), is coated onto adjuvant-loaded nanoparticle cores (CpG-NPs) to yield a nanoparticulate anticancer vaccine (CpG-CCNPs). Upon delivery to antigen presenting cells (blue), the vaccine formulation enables activation of T cells (tan) with multiple specificities. After detecting the antigens present on the tumor, the T cells are capable of initiating cancer cell death (gray).